AC IMMUNE SA SF-02 (F:IMR) — Stock Price

€2.22 EUR
▲ 0.23% today

AC IMMUNE SA SF-02 (F:IMR) is currently trading at €2.22 EUR, up 0.23% today. Over the past 52 weeks, shares have ranged between €1.77 and €3.32. This page tracks AC IMMUNE SA SF-02's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see IMR cash flow conversion.

AC IMMUNE SA SF-02 (IMR) Stock Price Chart — Daily History & Trading Volume

The chart below tracks AC IMMUNE SA SF-02's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.

AC IMMUNE SA SF-02 Income Statement — Revenue, Profit & Earnings by Year

AC IMMUNE SA SF-02's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue €3.57 Million €27.31 Million €14.80 Million €3.94 Million €0.00
Cost of Revenue — — — — —
Gross Profit — — — — —
Research & Development €56.44 Million €62.57 Million €54.61 Million €60.34 Million €62.28 Million
SG&A €11.65 Million €11.43 Million €10.58 Million €9.58 Million €10.88 Million
Total Operating Expenses €72.44 Million €79.69 Million €68.42 Million €74.78 Million €79.01 Million
Operating Income €-68.86 Million €-52.38 Million €-53.62 Million €-70.85 Million €-79.01 Million
EBITDA — — — — —
EBIT — — — — —
Interest Expense €191.00K €133.00K €176.00K €355.00K €581.00K
Income Before Tax €-70.45 Million €-50.91 Million €-54.22 Million €-70.74 Million €-72.99 Million
Income Tax Expense — — — — —
Net Income €-70.45 Million €-50.92 Million €-54.23 Million €-70.75 Million €-73.00 Million

AC IMMUNE SA SF-02 Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes AC IMMUNE SA SF-02's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets €154.25 Million €230.91 Million €182.81 Million €185.94 Million €261.44 Million
Total Current Assets €96.72 Million €171.99 Million €125.15 Million €128.09 Million €202.63 Million
Cash & Equivalents — — — — —
Short-term Investments €64.62 Million €129.21 Million €24.55 Million €91.00 Million €116.00 Million
Net Receivables — €0.00 €14.80 Million €0.00 —
Inventory — — — — —
Property, Plant & Equipment — — — — —
Goodwill — — — — —
Total Liabilities €109.37 Million €118.64 Million €22.17 Million €16.95 Million €29.46 Million
Total Current Liabilities €94.69 Million €100.84 Million €13.58 Million €11.48 Million €20.03 Million
Long-term Debt — — — — —
Net Debt — — — — —
Total Stockholder Equity €44.88 Million €112.27 Million €160.64 Million €168.99 Million €231.98 Million
Retained Earnings €-439.02 Million €-368.24 Million €-316.20 Million €-264.01 Million €-200.94 Million

AC IMMUNE SA SF-02 Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how AC IMMUNE SA SF-02 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow €-69.26 Million €65.84 Million €-60.41 Million €-73.57 Million €-65.69 Million
Capital Expenditures €900.00K €576.00K €801.00K €1.24 Million €2.63 Million
Free Cash Flow €-70.16 Million €65.27 Million €-61.21 Million €-74.81 Million €-68.32 Million
Investing Cash Flow — — — — —
Financing Cash Flow €-1.02 Million €-1.12 Million €43.25 Million €-1.35 Million €40.75 Million
Dividends Paid — — — — —
Stock-Based Compensation €4.40 Million €5.47 Million €4.37 Million €3.33 Million €4.13 Million
Depreciation €2.50 Million €2.16 Million €2.21 Million €2.36 Million €2.41 Million
Change in Cash €-6.74 Million €-40.57 Million €48.49 Million €-51.15 Million €-78.61 Million

AC IMMUNE SA SF-02 Earnings History — EPS Actual vs. Analyst Estimates

Track AC IMMUNE SA SF-02's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Nov 04, 2026 — -0.15 —
Aug 04, 2026 — -0.11 —
Apr 29, 2026 — -0.14 —
Mar 12, 2026 — -0.17 —
Nov 04, 2025 — -0.17 —
Aug 04, 2025 — — —
Apr 30, 2025 — — —
Mar 12, 2025 — — —